CS
STOK icon

Candriam SCA’s Stoke Therapeutics STOK Stock Holding History

Candriam SCA’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.7M Sell
480,136
-21,884
-4% -$702K 0.07% 231
2026
Q1 		$16.3M Buy
502,020
+55,330
+12% +$1.81M 0.08% 220
2025
Q4 		$14.2M Buy
+446,690
New +$13.4M 0.07% 223

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Candriam SCA's STOK Position: Q2 2026 in Review

Candriam SCA reduced its Stoke Therapeutics (STOK) stake by 4.4% in Q2 2026, selling an estimated $702K and leaving 480,136 shares worth $15.7M. The position accounts for 0.07% of the portfolio, ranked #231.

Candriam SCA first reported a position in STOK in Q4 2025 and has held it in 3 quarters since. The position peaked at $16.3M in Q1 2026. 198 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Candriam SCA held 480,136 shares of Stoke Therapeutics worth $15.7M as of Q2 2026.
  • Candriam SCA sold 21,884 Stoke Therapeutics shares in Q2 2026, an estimated $702K.
  • Stoke Therapeutics made up 0.07% of Candriam SCA's portfolio in Q2 2026, its #231 holding.
  • Candriam SCA first reported a position in Stoke Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Candriam SCA's Stoke Therapeutics position peaked at $16.3M in Q1 2026.
  • 198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.